Biomarker discovery and development for clinical research, diagnostics and therapy
monitoring in clinical trials have advanced rapidly in key areas of medicine—most notably …

Alzheimer disease (AD) is characterized by wide heterogeneity in cognitive and behavioural
syndromes, risk factors and pathophysiological mechanisms. Addressing this phenotypic …

Adult hippocampal neurogenesis (AHN) drops sharply during early stages of Alzheimer's
disease (AD), via unknown mechanisms, and correlates with cognitive status in AD patients …

Alzheimer's disease (AD) is a progressive neurodegenerative disease with a complex and
heterogeneous pathophysiology. The number of people living with AD is predicted to …

Alzheimer disease (AD) is the most common cause of dementia in older individuals (> 65
years) and has a long presymptomatic phase. Preventive therapies for AD are not yet …

Neuroinflammation commences decades before Alzheimer's disease (AD) clinical onset and
represents one of the earliest pathomechanistic alterations throughout the AD continuum …

Developing effective drugs for Alzheimer's disease (AD), the most common cause of
dementia, has been difficult because of complicated pathogenesis. Here, we report an …

Introduction Blood-based biomarkers of pathophysiological brain amyloid β (Aβ)
accumulation, particularly for preclinical target and large-scale interventions, are warranted …

Multi-pathway approaches for the treatment of complex polygenic disorders are emerging as
alternatives to classical monotarget therapies and microRNAs are of particular interest in …

Alzheimer's disease (AD) is characterized by amyloid (A) β peptide accumulation and
intracellular neurofibrillary tangles. New hypotheses have suggested that AD involves …